Skip directly to site content Skip directly to search


Español  Other Languages


An official website of the United States government Here's how you know
 Official icon**Official websites use .gov**
				A .gov website belongs to an official government organization in the United States. Lock icon**Secure .gov websites use HTTPS**
				A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
	CDC LogoCDC Logo
 Search

		Submit


Tuberculosis (TB)





Reported Tuberculosis in the United States, 2019						Print
																Related Pages
										Return to Main Menu
Table 51. Tuberculosis Cases and Percentages, by Completion of Tuberculosis Therapy (COT): Reporting Areas, 20171
Table 51. Tuberculosis Cases and Percentages, by Completion of Tuberculosis Therapy (COT): Reporting Areas, 2017
Reporting Area
Total Cases
Therapy ≤1 Year Indicated2,3,4
Therapy >1 Year Indicated3,5No.
COT ≤1 year(%)
COT(%)
No.
COT(%)**United States**
**9,082**
**7,399**
**(89.8)**
**(95.8)**
**531**
**(94.2)**Alabama
120
107
(87.9)
(95.3)
5
(100.0)Alaska
53
47
(91.5)
(93.6)
3
(100.0)Arizona
188
146
(92.5)
(97.3)
9
(100.0)Arkansas
85
76
(78.9)
(85.5)
2
(100.0)California
2,057
1,663
(90.0)
(96.6)
108
(93.5)Colorado
84
68
(91.2)
(94.1)
5
(100.0)Connecticut
63
49
(98.0)
(100.0)
4
(100.0)Delaware
15
9
(100.0)
(100.0)
3
(100.0)District of Columbia
36
30
(76.7)
(93.3)
1
(100.0)Florida
549
454
(95.2)
(97.6)
28
(96.4)Georgia
293
240
(86.3)
(95.4)
19
(100.0)Hawaii
116
97
(96.9)
(99.0)
9
(100.0)Idaho
10
9
(88.9)
(100.0)
1
(0.0)Illinois
334
273
(91.2)
(97.1)
11
(72.7)Indiana
100
84
(96.4)
(98.8)
5
(80.0)Iowa
47
39
(97.4)
(100.0)
3
(100.0)Kansas
29
21
(100.0)
(100.0)
6
(100.0)Kentucky
65
49
(98.0)
(100.0)
4
(100.0)Louisiana
141
119
(82.4)
(91.6)
4
(25.0)Maine
14
9
(100.0)
(100.0)
2
(100.0)Maryland
207
172
(84.3)
(93.6)
11
(90.9)Massachusetts
209
168
(94.6)
(99.4)
22
(90.9)Michigan
133
99
(96.0)
(96.0)
8
(87.5)Minnesota
178
138
(95.7)
(100.0)
22
(100.0)Mississippi
52
44
(86.4)
(90.9)
5
(100.0)Missouri
87
72
(73.6)
(84.7)
6
(100.0)Montana
3
3
(100.0)
(100.0)
0
...Nebraska
22
15
(66.7)
(80.0)
4
(75.0)Nevada
80
66
(98.5)
(98.5)
3
(100.0)New Hampshire
19
17
(88.2)
(88.2)
1
(100.0)New Jersey
283
212
(92.9)
(97.6)
19
(94.7)New Mexico
37
25
(96.0)
(100.0)
0
...New York State6
193
162
(92.6)
(98.8)
13
(100.0)New York City
608
494
(92.9)
(97.4)
49
(93.9)North Carolina
213
187
(93.6)
(97.3)
12
(100.0)North Dakota
14
13
(92.3)
(100.0)
0
...Ohio
149
124
(82.3)
(91.1)
8
(87.5)Oklahoma
54
48
(95.8)
(100.0)
5
(100.0)Oregon
69
61
(90.2)
(100.0)
3
(100.0)Pennsylvania
192
156
(75.6)
(92.3)
6
(66.7)Rhode Island
13
9
(77.8)
(88.9)
0
...South Carolina
101
87
(92.0)
(96.6)
4
(100.0)South Dakota
14
11
(100.0)
(100.0)
1
(100.0)Tennessee
124
105
(95.2)
(99.0)
6
(100.0)Texas
1,119
898
(82.6)
(90.6)
50
(96.0)Utah
29
24
(95.8)
(100.0)
4
(100.0)Vermont
3
2
(50.0)
(100.0)
0
...Virginia
204
176
(97.2)
(98.9)
17
(100.0)Washington
207
167
(93.4)
(95.2)
13
(92.3)West Virginia
16
13
(84.6)
(100.0)
1
(100.0)Wisconsin
49
40
(90.0)
(100.0)
6
(100.0)Wyoming
2
2
(100.0)
(100.0)
0
...American Samoa7
2
1
(0.0)
(0.0)
0
...Fed. States of Micronesia7
143
129
(94.6)
(94.6)
5
(100.0)Guam7
84
74
(91.9)
(94.6)
1
(100.0)Marshall Islands7
193
181
(31.5)
(32.0)
3
(0.0)N. Mariana Islands7
41
39
(94.9)
(94.9)
0
...Puerto Rico7
40
30
(73.3)
(96.7)
0
...Republic of Palau7
20
16
(93.8)
(93.8)
0
...U.S. Virgin Islands7
2
2
(0.0)
(0.0)
0
...1Most recent year for which data are available.2Initial isolate susceptible to rifampin (n = 5,497) or susceptibility unknown (n = 166); culture negative (n = 1,359); culture status unknown (n = 363).3Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed.4Therapy ≤1 year indicated in persons alive at diagnosis with an initial regimen of one or more drugs prescribed, who did not die within one year of initiating therapy. Excludes persons with initial isolate rifampin resistant, or patient with bone and joint disease, meningeal disease or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and those who moved out of the country within one year of initiating treatment.5Initial isolate rifampin resistant, or patient with meningeal disease or bone and joint disease, or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and those who did not move out of the country or die during treatment.6Excludes New York City.7Not included in U.S. totals.
**Note:** Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
Zero % (0.0) denotes <0.05%.
See Technical Notes for description of completion of therapy calculation.Table Printing Tips
							
					
							Last Reviewed:  October 26, 2020						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisData and Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City Reports To receive email updates about this page, enter your email address: Email Address			What's this?				Submit
 Error processing SSI file


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue